Tauopathies Comparison Matrix

Migration, Crosslink

📖

Tauopathies Comparison Matrix

active

wiki page Created: 2026-04-02T07:20:12 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-tauopathies-comparison

📖 Wiki Page

disease1261 wordssynced 2026-04-02

Tauopathies Comparison Matrix

Tauopathies are a group of neurodegenerative disorders characterized by the accumulation of abnormal [tau protein](/proteins/tau) aggregates in the brain. This comparison matrix covers four major tauopathies: Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Frontotemporal Lobar Degeneration with tau pathology (FTLD-tau).

Overview

| Feature | Alzheimer's Disease | Progressive Supranuclear Palsy | Corticobasal Degeneration | FTLD-tau (including CBD) |
|---------|---------------------|--------------------------------|---------------------------|--------------------------|
| Primary Protein | Tau (3R+4R) | Tau (4R) | Tau (4R) | Tau (3R or 4R depending on subtype) |
| Main Pathology | Neurofibrillary tangles, amyloid plaques | NFTs, tufted [astrocytes](/entities/astrocytes) | Astrocytic plaques, NFTs | Pick bodies (3R), CBD pathology |
| Main Genes | [APP](/genes/app), [PSEN1](/genes/psen1), [PSEN2](/genes/psen2), [APOE](/genes/apoe) | [MAPT](/genes/mapt) | [MAPT](/genes/mapt), [CBD](/genes/cbd) | [MAPT](/genes/mapt), [GRN](/genes/grn) |

Clinical Features Comparison

...

Tauopathies Comparison Matrix

Tauopathies are a group of neurodegenerative disorders characterized by the accumulation of abnormal [tau protein](/proteins/tau) aggregates in the brain. This comparison matrix covers four major tauopathies: Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Frontotemporal Lobar Degeneration with tau pathology (FTLD-tau).

Overview

| Feature | Alzheimer's Disease | Progressive Supranuclear Palsy | Corticobasal Degeneration | FTLD-tau (including CBD) |
|---------|---------------------|--------------------------------|---------------------------|--------------------------|
| Primary Protein | Tau (3R+4R) | Tau (4R) | Tau (4R) | Tau (3R or 4R depending on subtype) |
| Main Pathology | Neurofibrillary tangles, amyloid plaques | NFTs, tufted [astrocytes](/entities/astrocytes) | Astrocytic plaques, NFTs | Pick bodies (3R), CBD pathology |
| Main Genes | [APP](/genes/app), [PSEN1](/genes/psen1), [PSEN2](/genes/psen2), [APOE](/genes/apoe) | [MAPT](/genes/mapt) | [MAPT](/genes/mapt), [CBD](/genes/cbd) | [MAPT](/genes/mapt), [GRN](/genes/grn) |

Clinical Features Comparison

| Feature | Alzheimer's Disease | Progressive Supranuclear Palsy | Corticobasal Degeneration | FTLD-tau |
|---------|---------------------|--------------------------------|---------------------------|----------|
| Core Symptoms | Memory loss, cognitive decline | Vertical gaze palsy, falls, axial rigidity | Apraxia, alien limb, cortical sensory loss | Behavior/personality changes or language loss |
| Onset Age (typical) | 65-80 years | 60-70 years | 60-70 years | 45-65 years |
| Disease Duration | 8-12 years | 5-10 years | 5-8 years | 6-12 years |
| Motor Symptoms | Late, mild | Early, prominent (gaze palsy, falls) | Early, asymmetric (apraxia, dystonia) | Late, variable |
| Cognitive Profile | Amnestic, global deficits | Frontal/executive deficits | Language + executive deficits | Behavior or language (primary) |
| Speech | Normal initially | Dysarthria common | Nonfluent aphasia possible | Nonfluent or semantic |
| Autonomic | Usually mild | Moderate | Variable | Usually mild |
| Hallucinations | Late stage | Rare | Rare | Rare |

Genetics

| Feature | Alzheimer's Disease | Progressive Supranuclear Palsy | Corticobasal Degeneration | FTLD-tau |
|---------|---------------------|--------------------------------|---------------------------|----------|
| Sporadic Cases | ~95% | ~95% | ~60% | ~60% |
| Familial Cases | ~5% | ~5% | ~40% | ~40% |
| Major Risk Genes | [APP](/genes/app), [PSEN1](/genes/psen1), [PSEN2](/genes/psen2), [APOE4](/genes/apoe4), [TREM2](/genes/trem2) | [MAPT](/genes/mapt), [STX6](/genes/stx6) | [MAPT](/genes/mapt) | [MAPT](/genes/mapt), [GRN](/genes/grn) |
| Inheritance | Autosomal dominant (rare), complex | Usually sporadic | Usually sporadic | Autosomal dominant common |
| Tau Isoforms | 3R + 4R | 4R | 4R | 3R (Pick's) or 4R (CBD/PSP) |

Neuropathology

| Feature | Alzheimer's Disease | Progressive Supranuclear Palsy | Corticobasal Degeneration | FTLD-tau |
|---------|---------------------|--------------------------------|---------------------------|----------|
| Key Inclusions | Neurofibrillary tangles | NFTs, tufted astrocytes | Astrocytic plaques, CBD lesions | Pick bodies (Pick's), ballooned [neurons](/entities/neurons) |
| Tau Morphology | Paired helical filaments | Straight filaments | Straight filaments | 3R tau (Pick's), 4R tau (CBD) |
| Primary Regions | [Hippocampus](/brain-regions/hippocampus), [entorhinal cortex](/brain-regions/entorhinal-cortex) | Brainstem, basal ganglia | Motor [cortex](/brain-regions/cortex), basal ganglia | Frontal/temporal cortex |
| Amyloid | Present (Aβ plaques) | Absent | Absent | Absent (except AD overlap) |
| Cell Loss | Hippocampus, cortex | Substantia nigra, globus pallidus | Motor/premotor cortex | Frontotemporal cortex |

Affected Brain Regions

| Region | Alzheimer's Disease | Progressive Supranuclear Palsy | Corticobasal Degeneration | FTLD-tau |
|--------|---------------------|--------------------------------|---------------------------|----------|
| Frontal Cortex | Late involvement | Early | Early | Early, prominent |
| Temporal Cortex | Early | Late | Variable | Early, prominent |
| Parietal Cortex | Early | Late | Variable | Variable |
| Occipital Cortex | Late | Late | Late | Usually spared |
| Hippocampus | Very early | Late | Rare | Variable |
| Basal Ganglia | Moderate | Early, severe | Early, severe | Variable |
| Brainstem | Late | Early, severe | Midbrain | Usually spared |
| Cerebellum | Usually spared | Variable | Variable | Usually spared |

Treatment Approaches

| Feature | Alzheimer's Disease | Progressive Supranuclear Palsy | Corticobasal Degeneration | FTLD-tau |
|---------|---------------------|--------------------------------|---------------------------|----------|
| Symptomatic | [Cholinesterase inhibitors](/entities/cholinesterase-inhibitors), memantine | Limited | Limited | Limited |
| Cognitive | Cholinesterase inhibitors | None proven | None proven | None proven |
| Motor | Limited | Physical therapy | Botulinum toxin, therapy | Variable |
| Disease-Modifying | Aducanumab, [lecanemab](/entities/lecanemab) (anti-amyloid) | None approved | None approved | None approved |
| Clinical Trials | Anti-tau therapies in progress | Anti-tau therapies | Anti-tau therapies | Anti-tau therapies |

Biomarkers

| Feature | Alzheimer's Disease | Progressive Supranuclear Palsy | Corticobasal Degeneration | FTLD-tau |
|---------|---------------------|--------------------------------|---------------------------|----------|
| MRI | Hippocampal atrophy | Midbrain ("hummingbird"), PSP signs | Asymmetric cortical atrophy | Frontotemporal atrophy |
| PET | amyloid-PET positive | Tau-PET may show midbrain | Tau-PET variable | Tau-PET may show frontal |
| CSF Biomarkers | [Aβ42](/proteins/amyloid-beta) low, t-tau high, p-tau high | Tau elevated, Aβ normal | Tau elevated | Tau normal to elevated |
| DaT Scan | Usually normal | Reduced uptake | Reduced uptake | Usually normal |

Key Differential Features

| Feature | Alzheimer's Disease | Progressive Supranuclear Palsy | Corticobasal Degeneration | FTLD-tau |
|---------|---------------------|--------------------------------|---------------------------|----------|
| Hallmark Sign | Memory impairment | Vertical supranuclear gaze palsy | Alien limb phenomenon | Behavior change or language loss |
| Tau Isoform | 3R + 4R | 4R | 4R | 3R or 4R |
| Amyloid | Present | Absent | Absent | Absent |
| Age at Onset | Older | 60-70 | 60-70 | Younger (45-65) |
| Disease Progression | Gradual | Rapid | Variable | Variable |

Classification

4R-Tauopathies

[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[Corticobasal Degeneration](/diseases/corticobasal-degeneration)
[4R-Tauopathy Cell Vulnerability](/diseases/4r-tauopathy-cell-vulnerability)

3R-Tauopathies

Pick's Disease

3R+4R Tauopathies

[Alzheimer's Disease](/diseases/alzheimers-disease)

Cross-Reference Links

[Tau Protein](/proteins/tau)
[MAPT Gene](/genes/mapt)
[Alpha-Synucleinopathies](/diseases/alpha-synucleinopathies) - comparison with alpha-synucleinopathies
[Frontotemporal Lobar Degeneration](/diseases/frontotemporal-lobar-deeneration)
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[Corticobasal Degeneration](/diseases/corticobasal-degeneration)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Tau Isoform Classification

Mermaid diagram (expand to render)

Pathogenic Mechanisms Comparison

Mermaid diagram (expand to render)

References

[Masters et al., Alzheimer's disease: Nature Reviews Disease Primers (2023) (2023)](https://doi.org/10.1038/s41572-023-00457-w)

[Boxer et al., PSP: Clinical features, genetics and diagnosis (2022) (2022)](https://doi.org/10.1016/j.jns.2022.120399)

[Armstrong et al., CBD diagnostic criteria 2013 (2013) (2013)](https://doi.org/10.1212/WNL.0b013e3182a34950)

[Cagnin et al., FTLD classification and biomarkers (2021) (2021)](https://doi.org/10.1007/s00401-021-02341-x)

[Unknown, Dugger & Dickson, Tau isoforms in tauopathies (2022) (2022)](https://doi.org/10.1016/j.neurobiolaging.2022.03.015)

[Jansen et al., Anti-tau therapy clinical trials (2024) (2024)](https://doi.org/10.1002/alz.068756)

[Unknown, Frost & Diamond, Tau propagation mechanisms in neurodegenerative disease (2023) (2023)](https://doi.org/10.1038/s41583-023-00700-x)

[Neumann et al., 4R tauopathies: PSP, CBD, and AGD (2020) (2020)](https://doi.org/10.1007/s00401-020-02163-5)

[Gandhi et al., Tau PET in atypical tauopathies (2022) (2022)](https://doi.org/10.1038/s41582-022-00705-3)

[Kovacs et al., Neuropathologic classification of frontotemporal dementia (2021) (2021)](https://doi.org/10.1007/s00401-021-02294-3)

📖 View canonical wiki page →

Related Entities

diseases-tauopathies-comparison

▸Metadataorigin_type: v1_polymorphic_backfill

slug	diseases-tauopathies-comparison
kg_node_id	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b6c1fb6ca04f
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-tauopathies-comparison'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

95%

Debates

0

Incoming

19

Outgoing

42

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Tauopathies Comparison Matrix

Tauopathies Comparison Matrix

Overview

Clinical Features Comparison

Tauopathies Comparison Matrix

Overview

Clinical Features Comparison

Genetics

Neuropathology

Affected Brain Regions

Treatment Approaches

Biomarkers

Key Differential Features

Classification

4R-Tauopathies

3R-Tauopathies

3R+4R Tauopathies

Cross-Reference Links

See Also

External Links

Tau Isoform Classification

Pathogenic Mechanisms Comparison

References

💬 Discussion